Author(s): Kelly C.; Relph N.; Spencer S.; Chalmers J.D.; Crossingham I.; Felix L.M.; Evans D.J.; Milan S.J.
Source: Cochrane Database of Systematic Reviews; Mar 2018; vol. 2018 (no. 3)
Publication Date: Mar 2018
Publication Type(s): Review
Abstract:Background: Bronchiectasis is a chronic respiratory disease characterised by abnormal and irreversible dilatation and distortion of the smaller airways. Bacterial colonisation of the damaged airways leads to chronic cough and sputum production, often with breathlessness and further structural damage to the airways. Long-term macrolide antibiotic therapy may suppress bacterial infection and reduce inflammation, leading to fewer exacerbations, fewer symptoms, improved lung function, and improved quality of life. Further evidence is required on the efficacy of macrolides in terms of specific bacterial eradication and the extent of antibiotic resistance.
The following databases were searched:
EMBASE, MEDLINE, PsycINFO, BNI, CINAHL,
to find ELHT staff publications
Archives - past 2 years
Your Specialty or Professional Group